[ad_1] Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene therapy. LUND, Sweden, […]
Tag: Hansa Biopharma AB
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
[ad_1] IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ — Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced its full year and Q4 […]
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
[ad_1] The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment. LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) […]
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
[ad_1] The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment. LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) […]
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
[ad_1] LUND, Sweden, Oct. 30, 2024 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer […]
